SUN PHARMACEUTICAL INDUSTRIES INC 2023-07-19 Health serious FDA
Health · FDA · Recall #FDA-D-0914-2023
Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical… Recall
Issued July 19, 2023 · SUN PHARMACEUTICAL INDUSTRIES INC
In July 2023, SUN PHARMACEUTICAL INDUSTRIES INC recalled the Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical…, a serious health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing
What you should do
- 1 Stop using Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact SUN PHARMACEUTICAL INDUSTRIES INC to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Health
- Recall date
- July 19, 2023
- Units affected
- Not reported
- Sold at
- Distributed nationwide in the USA.
- Recall number
- FDA-D-0914-2023
- Made in
- United States
- Issuing agency
- FDA
In context
- SUN PHARMACEUTICAL INDUSTRIES INC has 34 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 903rd Health recall we've logged in 2023.